Drugs / JAB-30355
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06386146 | Jul 2024 → Jan 2027 expected | cancer | Jacobio Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JAB-30355 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06386146 ↗ |
| Route | Oral | “Oral administration” NCT06386146 ↗ |